Short answer
FDA-approved products are reviewed for specific uses. Compounded drugs are not FDA-approved, and FDA says it does not verify their safety, effectiveness, or quality before marketing.
Why compounding status matters
Compounding may be clinically appropriate in specific contexts, but the regulatory status and quality verification are different from FDA-approved products. First identify the product category; only then compare the evidence for the claimed effect.
Why FDA pages matter
FDA meetings, label changes, and warnings can change how a peptide claim should be read.
The compounding economics nobody shows you
Clinics often buy compounded peptides at pharmacy cost and set their own markup. Patients rarely see the difference. Asking what the pharmacy charges and what the clinic charges you is a reasonable question with a revealing answer.
What prescribers risk outside approved channels
Malpractice insurance generally does not cover prescribing non-FDA-approved injectable peptides. That is part of why the telehealth peptide market leans on scripted approvals and gray-market referrals rather than conventional clinical care.
Sources
- 1.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 2.
Accessed 2026-06-08.
FDA distinguishes approved semaglutide products from compounded semaglutide products and describes dosing-error concerns.
- 3.
FDA. FDA Approves New Medication for Chronic Weight Management 2023.
Accessed 2026-06-08.
FDA approval announcement for Zepbound, a tirzepatide product for chronic weight management in specified adults.